<DOC>
	<DOC>NCT00362466</DOC>
	<brief_summary>The purpose of this clinical research study is to compare the rate of complete cytogenetic response of dasatinib to imatinib therapy at 6 months after randomization in chronic phase CML patients. The safety of this treatment will also be studied.</brief_summary>
	<brief_title>A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Men and women ≥18 years diagnosed with Chronic Phase Philadelphia chromosome positive (CP Ph+) CML who have failed to achieve CCyR after 318 months of therapy with imatinib 400 mg Treatment initiation with imatinib 400 mg within 6 months of initial CML diagnosis Able to tolerate chronic administration of imatinib at the highest dose (400600 mg) the subject has received in the past Eastern Cooperative Oncology Group Performance Status (ECOG PS) 02 Adequate hepatic and renal function Eligible and willing to undergo immediate autologous/allogeneic stem cell transplant Previous diagnosis of accelerated/blast crisis CML Subjects with clonal evolution in Ph+ cells observed in ≥2 metaphases Previous documentation of T315I mutation Uncontrolled or significant cardiovascular disease Serious uncontrolled medical disorder/active infection History of significant bleeding disorder unrelated to CML Intolerance to imatinib ≥400 mg Concurrent malignancies other than CML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Leukemia (chronic myeloid leukemia - chronic phase)</keyword>
</DOC>